NRBO - NeuroBo to Present at the H.C. Wainwright 7th Annual NASH Investor Conference
PR Newswire
BOSTON , Oct. 17, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer, and Robert Homolka , Senior Vice-President of Clinical Operations, will present a company overview at the H.C. Wainwright 7 th Annual NASH Investor Conference on Tuesday, October 24 th at 2:30 pm ET .
Mr. Kim and Mr. Homolka will also be available for virtual one-on-one meetings during the event. Institutional investors who are registered for the conference can request a meeting through the conference platform.
A live webcast of Mr. Kim's and Mr. Homolka's presentation will be available on the Event Calendar page of the NeuroBo website at: https://www.neurobopharma.com/events-presentations/event-calendar . An archived replay will be available on the company's website for a period of 90 days after the conference.
About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases. The company is currently developing DA-1241 for the treatment of Non-Alcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM), and is developing DA-1726 for the treatment of obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist , which promotes the release of key gut peptides GLP-1, GIP , and PYY . In preclinical studies, DA-1241 demonstrated positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis , hepatic inflammation, and liver fibrosis, while also improving glucose control. DA-1726 is a novel oxyntomodulin ( OXM ) analogue that acts as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor ( GCGR ) dual agonist . OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR , thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists . For more information, please visit www.neurobopharma.com .
Contact:
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
SOURCE NeuroBo Pharmaceuticals, Inc.
Company Name: | NeuroBo Pharmaceuticals Inc. |
Stock Symbol: | NRBO |
Market: | NASDAQ |
Website: | neurobopharma.com |
News, Short Squeeze, Breakout and More Instantly...
Market Wire News is a media platform, the information on this page was provided by PR Newswire via Quote Media. Read our full disclaimer.